When was Rampart Bioscience founded?

Rampart Bioscience was founded in 2020.

Where is Rampart Bioscience located?

Rampart Bioscience is headquartered in La Jolla, United States. It is registered at Tucson, Arizona.

Who is the current CEO of Rampart Bioscience?

Louis Breton of Rampart Bioscience. They have also founded 1 company.

Is Rampart Bioscience a funded company?

Rampart Bioscience is a funded company, having raised a total of $125M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of Rampart Bioscience?

Rampart Bioscience's latest funding was a $***** Series A round on Oct 24, 2023, with participation from 4 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.39B in funding in 2026 to date.

Where does Rampart Bioscience rank among its competitors?

Rampart Bioscience ranks 228th amongst 548 active competitors, of which 200 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Sirnaomics, which secured $17.7M in Sep, 2025.

Who are the top competitors of Rampart Bioscience?

Rampart Bioscience's top competitors include Alnylam, Spark Therapeutics and Forge Biologics. Among them, Sirnaomics secured the most recent funding round in September, 2025.

Rampart Bioscience - 2026 Company Profile, Team, Funding & Competitors

Company Details

Biotechnology company developing novel DNA based medicines. It is a biotech company that researches and develops gene based therapies, gene delivery, protein sciences, and clinical translation for treating metabolic disorders. The company combines scientific research abilities in gene delivery, protein sciences, and clinical translation to generate optimized treatments in a re disable, non viral manner. It offers drug development and disease management solution for the treatment of hypophosphatasia and genetic diseases affecting the liver.

Website: rampartbio.com
Registered Address: Tucson, Arizona

Key Metrics

Founded Year

2020

Location

La Jolla, United States

Stage

Series A

Total Funding

$125M in 2 rounds

Latest Funding Round

Series A, Oct 24, 2023, $*****

Investors

Orbimed & 3 more

Ranked

228^th among 548 active competitors

Similar Companies

Alnylam & 683 more

View Rampart Bioscience's full profile

Rampart Bioscience is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
RAMPART BIOSCIENCE, INC. CIN: 833688007 , United States, Active	Dec 31, 1999	-	38 (As on Dec 31, 2024)	-

Rampart Bioscience has raised a total funding of $125M over 2 rounds. Its latest funding round was a Series A round on Oct 24, 2023 for $*****. 4 investors participated in its latest round. Rampart Bioscience has 4 institutional investors.

Here is the list of recent funding rounds of Rampart Bioscience:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 24, 2023	6545518	Series A	8462005	2809937	1592715	4381638

Access funding benchmarks and valuations. Sign up today!

View details of Rampart Bioscience's funding rounds and investors

The founders of Rampart Bioscience are Louis Breton and Jeffrey Bartlett. Louis Breton is the CEO of Rampart Bioscience.

Here are the details of Rampart Bioscience's key team members:

Louis Breton: Co-Founder & CEO of Rampart Bioscience.
Jeffrey Bartlett: Co-Founder & CIO of Rampart Bioscience.

View details of Rampart Bioscience's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rampart Bioscience include Alnylam, Spark Therapeutics and Forge Biologics. Here is the list of Top 10 competitors of Rampart Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	71/100
4th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
8th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	68/100
9th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100
10th	Sirnaomics 2007, Gaithersburg (United States), Public	Developer of RNA based therapeutics for the treatment of cancer and fibrosis disease	$267M	Rotating Boulder Fund, Walvax & 16 others	67/100
228th	Rampart Bioscience 2020, La Jolla (United States), Series A	Biotechnology company developing novel DNA based medicines	$125M	RA Capital Management, Orbimed & 2 others	38/100